<DOC>
	<DOCNO>NCT02161744</DOCNO>
	<brief_summary>The purpose study : 1.- ass safety tolerability autologous adipose derived stem cell ( aADSC ) administer intravenously patient chronic obstructive pulmonary disease , 2.- ass therapy result less decrease lung function parameter ( FEV1 , FEV1/FVC 6 min walk distance ) compare control baseline 6 week . Patients follow 12 month therapy .</brief_summary>
	<brief_title>Safety , Tolerability Preliminary Efficacy Adipose Derived Stem Cells Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>STUDY DESIGN This Phase I open- label single-dose study subject significant COPD . This expand safety cohort . The investigator enroll minimum 60 subject . 6 week data FEV1 , FEV1/FVC , DLCO 6 min walk distance value collect patient enrol study ( Baseline 6 week ) . Prior stem cell treatment , patient assess 6 week pulmonary function test 6 min walk test . Then , patient receive infusion stromal vascular fraction cell contain aADSC ( single intravenous dose ) . The standard therapy COPD patient interrupted duration study . Safety monitor ongoing basis , interim safety review conduct Investigator ( ) Sponsor first 20 patient enrol treat .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>1 . Males Females â‰¥18 year . 2 . Cognitive competitiveness . 3 . Diagnosis least moderate COPD ( postbronchodilator FEV1/FVC &lt; 70 % ( &lt; 0.7 ) , FEV1 &lt; 80 % predict ) . 4 . Diffusing capacity impairment ( DLCO ) assess single breath test ( correct alveolar volume , 'DLVA ' ) . 5 . Life expectancy great 12 month . 6 . Ability understand provide sign informed consent , designated legal guardian spouse legally able willing make decision subject 's behalf . 7 . Reasonable expectation patient receive standard posttreatment care attend schedule safety followup visit . 8 . No change active pulmonary medication heart failure two week prior enrollment . 10 . Written informed consent . 11 . Nonsmoker Past smoker , 20 packyears history 1 . Current smoker . 2 . Unstable coronary disease . 3 . Patients industrial exposure silica and/or asbestos giant bulla . 4 . Uncontrolled seizure disorder . 5 . Dementia . 6 . Presence immune deficiency autoimmune disease . 7 . Alpha 1 antitrypsin deficiency . 8 . Cor pulmonale diastolic heart failure NYHA class III IV 9 . Type 1 diabetes mellitus 10 . Complicated type 2 diabetes mellitus . 11 . Active tuberculosis severe lung damage due tuberculosis ( extensive cavitation ) . 12 . History cancer within past 5 year . 13 . Clinicallysignificant hematologic , hepatic , renal impairment determine screen clinical laboratory test . 14 . Systemic corticosteroid , cytostatics , immunosuppressive drug therapy ( cyclophosphamide , methotrexate , cyclosporine , azathioprine , etc . ) , DNA deplete cytotoxic drug take within four week prior study treatment . 15 . Porphyria . 16 . Allergy sodium citrate `` caine '' type local anesthetic . 17 . Abnormal finding could include : know HIV infection immunodeficiency state , chronic active viral infection ( hepatitis B C ) , acute systemic infection ( defined patient undergo treatment antibiotic ) , gastrointestinal tract bleeding , severe acute concomitant illness injury .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Adipose derive stem cell</keyword>
	<keyword>Stromal vascular fraction cell</keyword>
	<keyword>Pulmonary Function Tests</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
</DOC>